{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:03:58Z","timestamp":1792116238680,"version":"4.4.0"},"reference-count":73,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Digital therapeutics (DTx) are software-driven interventions that provide personalized, evidence-based treatments for various medical conditions. China\u2019s rapid technological adoption, large population, and supportive government policies position it as a potential global leader in DTx. However, challenges remain in clinical trial standardization, regulatory approval, product development, and reimbursement models. A comprehensive assessment of clinical evidence, commercialization trends, and regulatory frameworks is essential for understanding China\u2019s evolving DTx ecosystem and its global implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study systematically reviews and analyzes the DTx landscape in China, focusing on clinical trials, commercial products, regulatory frameworks, and pricing and reimbursement models. The findings provide insights for countries aiming to develop, regulate, and integrate DTx solutions into health care systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This comprehensive review integrates multiple methodological approaches to examine different aspects of the DTx ecosystem in China. We conducted a systematic review and meta-analysis to evaluate clinical trials, searching PubMed, Google Scholar, IEEE, Web of Science, and ScienceDirect until July 2024. Meta-analyses used random-effects models, reporting results as standardized mean differences (SMDs) and 95% CIs. For commercial products, a scoping review using the National Medical Products Administration database was performed. Regulatory policies were systematically identified through a manual review of official government sources, while pricing and reimbursement models were analyzed through a comprehensive assessment of public and private insurance policies, government initiatives, and commercial pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>: A total of 96 clinical trials on DTx in China were identified, with cognitive disorders (n=21, 22%) and diabetes (n=20, 21%) being the most frequently studied, followed by cardiovascular diseases (n=8, 8%), sleeping disorders (n=6, 6%), and smoking cessation (n=6, 6%). Meta-analysis for diabetes DTx showed a trend toward improved hemoglobin A1c levels in digital intervention groups compared to controls (SMD \u22120.96, 95% CI \u22122.03 to 0.11) but did not reach statistical significance (I\u00b2=97%). Meta-analysis for cognitive disorder DTx showed significant improvement in global cognitive function in DTx-treated participants (SMD 0.65, 95% CI 0.37-0.94), despite notable heterogeneity (I\u00b2=71.7%). The commercial landscape analysis identified 97 active DTx solutions, primarily targeting cognitive impairment (38 companies), ophthalmic diseases (30 companies), and respiratory diseases (5 companies). The regulatory review highlighted China\u2019s reliance on general medical device policies under the National Medical Products Administration rather than DTx-specific regulations, with emerging regional innovation policies supporting industry growth. Pricing analysis revealed diverse reimbursement models, including value-based pricing, private insurance partnerships, and government-facilitated programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>China has made substantial progress in DTx development but still faces challenges in clinical trial standardization, regulatory approval, and reimbursement. Key factors driving DTx adoption include targeted indications, standardized clinical trials, streamlined regulation, and diversified pricing models. China\u2019s experience provides valuable lessons for other countries with emerging digital health ecosystems as they develop DTx research, regulations, and integration strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>PROSPERO CRD42024615584; https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024615584<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/70955","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T23:35:06Z","timestamp":1744587306000},"page":"e70955","source":"Crossref","is-referenced-by-count":11,"title":["Digital Therapeutics in China: Comprehensive Review"],"prefix":"10.2196","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-0375","authenticated-orcid":false,"given":"Nan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2355-4668","authenticated-orcid":false,"given":"Xiru","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0438-1389","authenticated-orcid":false,"given":"Yuxi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-7220","authenticated-orcid":false,"given":"Guanqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8821-4166","authenticated-orcid":false,"given":"Chanchan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-2388","authenticated-orcid":false,"given":"Man Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6752-797X","authenticated-orcid":false,"given":"Yih Chung","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-1264","authenticated-orcid":false,"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5652-9127","authenticated-orcid":false,"given":"Keqin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-023-00777-z"},{"key":"ref2","unstructured":"Digital therapeutics in ChinaDigital Therapeutics Alliance20242025-04-22https:\/\/dtxalliance.org\/wp-content\/uploads\/2021\/09\/DTA_DTx-Overview_China-1.pdf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_105_20"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-00370-8"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4972"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00244-3"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4258\/hir.2022.28.3.188"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bjc.12286"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2019.01963"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30427-1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.0295"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100700"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00228-0"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(22)00232-8"},{"key":"ref15","unstructured":"The rise of digital therapeutics opportunities in ChinaEVERSANA20222025-04-22https:\/\/www.eversana.com\/wp-content\/uploads\/2021\/06\/POV_DigitalTherapeuticsChina_EVERSANA.pdf"},{"key":"ref16","unstructured":"ParekhAChina digital therapeutics market analysis\u200bInsights1020232025-04-22https:\/\/www.insights10.com\/report\/china-digital-therapeutics-market-analysis\/"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.01.009"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2021.104110"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01292-9"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1384318"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101691"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac213"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14779"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215685"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2196\/41099"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2196\/40420"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2021.09.001"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2020.0123"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13031"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275251"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.926719"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2196\/15401"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2196\/10664"},{"issue":"12","key":"ref35","first-page":"8848","volume":"7","author":"Zhou, P","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.03.018"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.23736\/S1973-9087.19.05899-4"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4822"},{"key":"ref39","unstructured":"Medical device databaseNational Medical Products Administration20242025-04-22https:\/\/www.nmpa.gov.cn\/datasearch\/home-index.html#category=ylqx"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/02692155211032372"},{"key":"ref41","unstructured":"Guiding opinions of the state council on promoting and regulating the application and development of healthcare big dataThe General Office of the State Council on Promoting and Regulating20162025-04-22https:\/\/www.gov.cn\/zhengce\/content\/2016-06\/24\/content_5085091.htm"},{"key":"ref42","unstructured":"Action outline for promoting high-quality development of the health industry (2019-2022)National Develepment Reform Commission2025-04-22https:\/\/www.ndrc.gov.cn\/xxgk\/zcfb\/tz\/201909\/t20190929_1181930.html"},{"key":"ref43","unstructured":"Regulations on supervision and administration of medical devicesState Council of the People's Republic of China20212025-04-22https:\/\/www.gov.cn\/zhengce\/content\/2021-03\/18\/content_5593739.htm"},{"key":"ref44","unstructured":"The provisions for medical device registration and filing (SAMR Decree No.47)State Administration for Market Regulation20212025-04-22https:\/\/www.gov.cn\/gongbao\/content\/2021\/content_5654783.htm"},{"key":"ref45","unstructured":"Guiding principles for technical review of mobile medical device registrationNational Medical Products Administration20172024-04-22https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/ylqx\/ylqxjgdt\/20171229135201645.html"},{"key":"ref46","unstructured":"Guiding principles for classifying and defining artificial intelligence medical software productsNational Medical Products Administration20212025-04-22https:\/\/www.nmpa.gov.cn\/ylqx\/ylqxggtg\/20210708111147171.html?type=pc&m="},{"key":"ref47","unstructured":"Guiding principles for clinical evaluation of medical devicesNational Medical Products Administration20212025-04-22https:\/\/www.nmpa.gov.cn\/ylqx\/ylqxggtg\/20210928170338138.html?type=pc&m="},{"key":"ref48","unstructured":"Implementation notice on matters related to the \"Measures for the supervision and administration of medical device production\" and the \"Measures for the supervision and administration of medical device distributionNation Medical Products Administration20222025-04-22https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/yaowen\/ypjgyw\/ylqxyw\/20220323140457133.html"},{"key":"ref49","unstructured":"Measures for the supervision and administration of medical device productionState Administration for Market Regulation20222025-04-22https:\/\/www.gov.cn\/gongbao\/content\/2022\/content_5691002.htm"},{"key":"ref50","unstructured":"Guiding principles for technical review of medical device software registrationNational Medical Products Administration20222025-04-22https:\/\/www.ccfdie.org\/cn\/yjxx\/ylqx\/webinfo\/2022\/03\/1648289422496885.htm"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1036"},{"key":"ref52","unstructured":"Catalogue of medical devices exempt from clinical trials (Notice No. 71 of the National Medical Products Administration in 2021)National Medical Products Administration20212025-04-22https:\/\/www.ccfdie.org\/cn\/yjxx\/ylqx\/webinfo\/2021\/01\/1608326624293831.htm"},{"key":"ref53","unstructured":"Guiding principles for technical review of medical device network security registrationNational Medical Products Administration20222025-04-22http:\/\/www.cjpi.org.cn\/zryyxxw\/ylqx\/cfdztz\/webinfo\/2022\/03\/1648289422686436.htm"},{"issue":"4","key":"ref54","volume":"2","author":"Wang, Z","year":"2024","journal-title":"Digit Med Health"},{"key":"ref55","unstructured":"Measures to accelerate the development of the digital therapeutics industry in Hainan ProvinceThe People's Government of Hainan Province20222025-04-22https:\/\/en.hainan.gov.cn\/hainan\/zmgxwfb\/202210\/a49a402892bd4228bb1037c9bc1c5f28.shtml"},{"key":"ref56","unstructured":"The fast-track process for digital health applications (DiGA) according to section 139e SGB V. A guide for manufacturers, service providers and usersFederal Institute for Drug and Medical Devices20202025-04-22https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/EN\/MedicalDevices\/DiGA_Guide.html"},{"key":"ref57","unstructured":"Digitale gesundheitsanwendungen [Digital health applications]The Federal Institute for Drugs and Medical Devices20222025-04-22https:\/\/diga.bfarm.de\/de\/verzeichnis"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.854665"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2021.667016"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2196\/48000"},{"key":"ref61","unstructured":"Shanghai launches a new inclusive brain health insurance plan focused on preventionChina Banking and Insurance News20242025-04-22http:\/\/www.cbimc.cn\/content\/2024-07\/30\/content_525300.html?share_token=7ccaa2a4-c11c-41d6-9329-8f55a13020f7"},{"key":"ref62","unstructured":"Hainan accelerates the building of a digital therapy innovation highlandThe People's Government of Hainan Province20242025-04-22http:\/\/hq.news.cn\/20240415\/5a58f746c8e64e5986d0b15fcb12bf0c\/c.html"},{"key":"ref63","unstructured":"Zhong an insurance launches 'Brain Worry-Free Dementia Protection Insurance' to care for older adultsChina Securities Journal20212025-04-22https:\/\/www.cs.com.cn\/bx\/202110\/t20211014_6210505.html"},{"key":"ref64","unstructured":"2023 digital therapy industry white paperVBdata20232025-04-22https:\/\/www.vbdata.cn\/1518940096"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.52937\/hira.22.2.1.47"},{"key":"ref66","doi-asserted-by":"crossref","DOI":"10.1201\/9781003017288","author":"Sverdlov, O","year":"2022","journal-title":"Digital Therapeutics: Strategic, Scientific, Developmental, and Regulatory Aspects"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1159\/000506861"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.2196\/30503"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2196\/19684"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.2196\/14210"},{"key":"ref71","unstructured":"510(k) premarket notificationFood and Drug Administration20222025-04-22https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMN\/pmn.cfm"},{"key":"ref72","unstructured":"Hainan provincial drug administration approves the listing of a digital therapy productHainan Medical Products Administration20242025-04-22https:\/\/amr.hainan.gov.cn\/himpa\/ztzl\/xxgcddesdjs\/202402\/t20240209_3593105.html"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13391"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jmir.org\/2025\/1\/e70955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:00:00Z","timestamp":1782842400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2025\/1\/e70955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":73,"URL":"https:\/\/doi.org\/10.2196\/70955","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.70955","asserted-by":"object"}]},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}